BR112023021959A2 - Compostos para o uso no tratamento de distúrbios hiperproliferativos - Google Patents
Compostos para o uso no tratamento de distúrbios hiperproliferativosInfo
- Publication number
- BR112023021959A2 BR112023021959A2 BR112023021959A BR112023021959A BR112023021959A2 BR 112023021959 A2 BR112023021959 A2 BR 112023021959A2 BR 112023021959 A BR112023021959 A BR 112023021959A BR 112023021959 A BR112023021959 A BR 112023021959A BR 112023021959 A2 BR112023021959 A2 BR 112023021959A2
- Authority
- BR
- Brazil
- Prior art keywords
- hyperproliferative disorders
- compounds
- treatment
- treating
- derivatives
- Prior art date
Links
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical class NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 abstract 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382343.8A EP4079304A1 (en) | 2021-04-21 | 2021-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
| PCT/EP2022/060579 WO2022223704A1 (en) | 2021-04-21 | 2022-04-21 | Compounds for use in the treatment of hyperproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021959A2 true BR112023021959A2 (pt) | 2023-12-26 |
Family
ID=75674747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021959A BR112023021959A2 (pt) | 2021-04-21 | 2022-04-21 | Compostos para o uso no tratamento de distúrbios hiperproliferativos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208998A1 (enExample) |
| EP (2) | EP4079304A1 (enExample) |
| JP (1) | JP2024515705A (enExample) |
| KR (1) | KR20240013112A (enExample) |
| CN (1) | CN117320715A (enExample) |
| AU (1) | AU2022260529A1 (enExample) |
| BR (1) | BR112023021959A2 (enExample) |
| CA (1) | CA3216090A1 (enExample) |
| IL (1) | IL307868A (enExample) |
| MX (1) | MX2023012457A (enExample) |
| WO (1) | WO2022223704A1 (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2609912T3 (es) * | 2007-06-22 | 2017-04-25 | Hydra Biosciences, Inc. | Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 |
-
2021
- 2021-04-21 EP EP21382343.8A patent/EP4079304A1/en not_active Withdrawn
-
2022
- 2022-04-21 CN CN202280035450.7A patent/CN117320715A/zh active Pending
- 2022-04-21 BR BR112023021959A patent/BR112023021959A2/pt unknown
- 2022-04-21 US US18/556,456 patent/US20240208998A1/en active Pending
- 2022-04-21 EP EP22723682.5A patent/EP4326262A1/en active Pending
- 2022-04-21 JP JP2023564537A patent/JP2024515705A/ja active Pending
- 2022-04-21 KR KR1020237040063A patent/KR20240013112A/ko active Pending
- 2022-04-21 WO PCT/EP2022/060579 patent/WO2022223704A1/en not_active Ceased
- 2022-04-21 IL IL307868A patent/IL307868A/en unknown
- 2022-04-21 MX MX2023012457A patent/MX2023012457A/es unknown
- 2022-04-21 AU AU2022260529A patent/AU2022260529A1/en active Pending
- 2022-04-21 CA CA3216090A patent/CA3216090A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515705A (ja) | 2024-04-10 |
| WO2022223704A1 (en) | 2022-10-27 |
| IL307868A (en) | 2023-12-01 |
| MX2023012457A (es) | 2023-11-22 |
| EP4079304A1 (en) | 2022-10-26 |
| CA3216090A1 (en) | 2022-10-27 |
| KR20240013112A (ko) | 2024-01-30 |
| AU2022260529A1 (en) | 2023-11-09 |
| US20240208998A1 (en) | 2024-06-27 |
| CN117320715A (zh) | 2023-12-29 |
| EP4326262A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112022017393A2 (pt) | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto | |
| BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
| BR112021016620A2 (pt) | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112023014973A2 (pt) | Derivados de urolitina e métodos de uso dos mesmos | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| BR112022022452A2 (pt) | Inibidores de il4i1 e métodos de uso | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| MX394245B (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| ZA201906327B (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| BR112019018028A2 (pt) | Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| BR112019000897A2 (pt) | sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão. | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112018016396A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar um distúrbio |